메뉴 건너뛰기




Volumn 46, Issue 6, 2005, Pages 843-846

A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9

Author keywords

Cytochrome P 450 CYP2C9; Pharmacogenetics; Polymorphism; Prothrombin time; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; IMIDAPRIL; PROTHROMBIN; SPIRONOLACTONE; TEPRENONE; VITAMIN K GROUP; WARFARIN;

EID: 30644469762     PISSN: 05135796     EISSN: 05135796     Source Type: Journal    
DOI: 10.3349/ymj.2005.46.6.843     Document Type: Article
Times cited : (3)

References (18)
  • 1
    • 0031841377 scopus 로고    scopus 로고
    • Cytochrome P450C9: An enzyme of major importance in human drug metabolism
    • Miners JO, Birkett DJ. Cytochrome P450C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45;525-38.
    • (1998) Br J Clin Pharmacol , vol.45 , pp. 525-538
    • Miners, J.O.1    Birkett, D.J.2
  • 2
    • 0141832724 scopus 로고    scopus 로고
    • Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin
    • Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 2003;3:202-14.
    • (2003) Pharmacogenomics J , vol.3 , pp. 202-214
    • Takahashi, H.1    Echizen, H.2
  • 3
    • 0034872136 scopus 로고    scopus 로고
    • Pharmacogenetics of warfarin elimination and its clinical implications
    • Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharma-cokinet 2001/40:587-603.
    • (2001) Clin Pharma-cokinet , vol.40 , pp. 587-603
    • Takahashi, H.1    Echizen, H.2
  • 4
    • 0033608466 scopus 로고    scopus 로고
    • Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    • Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1997;353:717-9.
    • (1997) Lancet , vol.353 , pp. 717-719
    • Aithal, G.P.1    Day, C.P.2    Kesteven, P.J.3    Daly, A.K.4
  • 5
    • 0031015345 scopus 로고    scopus 로고
    • Human P450 metabolism of warfarin
    • Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74.
    • (1997) Pharmacol Ther , vol.73 , pp. 67-74
    • Kaminsky, L.S.1    Zhang, Z.Y.2
  • 6
    • 0037565623 scopus 로고    scopus 로고
    • Pharmacogenetics of oral anticoagulants
    • Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003;13:247-52.
    • (2003) Pharmacogenetics , vol.13 , pp. 247-252
    • Daly, A.K.1    King, B.P.2
  • 7
    • 0037012465 scopus 로고    scopus 로고
    • Association between CYP2C9 genetic variants and anticoagutation-related outcomes during warfarin therapy
    • Higahi MK, Veenstra DL, Kondo LM, Wittkowskv AK, Srinouanprachanh SL, Farin FL, et at. Association between CYP2C9 genetic variants and anticoagutation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-8.
    • (2002) JAMA , vol.287 , pp. 1690-1698
    • Higahi, M.K.1    Veenstra, D.L.2    Kondo, L.M.3    Wittkowskv, A.K.4    Srinouanprachanh, S.L.5    Farin, F.L.6
  • 9
    • 0031807762 scopus 로고    scopus 로고
    • Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2Cl9 genotypes
    • Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2Cl9 genotypes. Clin Pharmacol Ther 1998;63:519-28.
    • (1998) Clin Pharmacol Ther , vol.63 , pp. 519-528
    • Takahashi, H.1    Kashima, T.2    Nomizo, Y.3    Muramoto, N.4    Shimizu, T.5    Nasu, K.6
  • 10
    • 0036914221 scopus 로고    scopus 로고
    • Influence of C-YP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
    • Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of C-YP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002;72:702-10.
    • (2002) Clin Pharmacol Ther , vol.72 , pp. 702-710
    • Scordo, M.G.1    Pengo, V.2    Spina, E.3    Dahl, M.L.4    Gusella, M.5    Padrini, R.6
  • 11
    • 0036263813 scopus 로고    scopus 로고
    • Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data
    • Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-63.
    • (2002) Pharmacogenetics , vol.12 , pp. 251-263
    • Lee, C.R.1    Goldstein, J.A.2    Pieper, J.A.3
  • 14
    • 0003880934 scopus 로고    scopus 로고
    • Human cytochrome P450 (CYP) genes
    • Available from: URL
    • Ingelman-Sunberg M, Nebert DW, Daly AK. Human cytochrome P450 (CYP) genes. Available from: URL: http://www.imm.ki.se/CYPalleles/cyp2c9.htm
    • Ingelman-Sunberg, M.1    Nebert, D.W.2    Daly, A.K.3
  • 17
    • 0041379113 scopus 로고    scopus 로고
    • Clinical and functional assessment after anticoagulant therapy of acute deep vein thrombosis involving the lower limb
    • Huh SH, Kim DI, Kim ES, Lee BB, Moon JY, Joh JH. Clinical and functional assessment after anticoagulant therapy of acute deep vein thrombosis involving the lower limb. Yonsei Med J 2003;44:686-93.
    • (2003) Yonsei Med J , vol.44 , pp. 686-693
    • Huh, S.H.1    Kim, D.I.2    Kim, E.S.3    Lee, B.B.4    Moon, J.Y.5    Joh, J.H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.